| Name | Title | Contact Details |
|---|
Perspectives International is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
03 Innovations Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
HealthCube ensures that accurate diagnosis is within easy and convenient reach of billions of people in both developed and developing economies. HealthCube designs and manufactures point-of-care diagnostic devices to enhance the quality of primary care in diverse settings. HealthCube`s multiparametric technology can test for over 30 parameters including blood glucose, hemoglobin, blood pressure, detect infectious diseases markers, and even perform ECGs. Their easy-to-use and portable devices are medical grade, clinically validated, and digitally enabled, with results available instantly. HealthCube is an ISO 13485 certified company which has received certification from Central Drugs Standard Control Organization (CDSCO) and European CE. HealthCube is backed by global marquee investors including Alkemi Ventures, Perot-Jain Ventures, Acumen, and SV Latam Capital. As of date, over one million beneficiaries have been registered on HealthCube Ecosystem and 2.5 million tests have been performed.
Mountain West Medical is a Boise, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack